Share this video  

ASCO 2021 | Comparing therapy benefit from initially HER2 positive or negative metastatic breast cancer patients

Hans-Christian Kolberg, MD, Marien Hospital Bottrop, Bottrop, Germany, discusses the results of an analysis from the PRAEGNANT prospective breast cancer registry (NCT02338167), comparing progression-free survival (PFS) with standard HER2 targeted therapies between patients with tumors initially HER2-negative and switched to HER2 positive and patients with tumors that were initially HER2 positive adjusted for age and hormone receptor status. In this small cohort, median PFS and 1- and 2-year PFS rates seem to be better in patients HER2 positive at initial diagnosis receiving standard HER2 directed therapies. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.